{"id":"W2624246814","doi":"10.1097/spc.0000000000000277","title":"Current management of metastatic renal cell carcinoma: evolving new therapies","year":2017,"lang":"en","type":"review","venue":"Current Opinion in Supportive and Palliative Care","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Sunitinib; Everolimus; Pazopanib; Temsirolimus; Cabozantinib; Axitinib; Lenvatinib; Sorafenib; Oncology; Renal cell carcinoma; Bevacizumab; Internal medicine; Tyrosine-kinase inhibitor; Nivolumab; PI3K/AKT/mTOR pathway; Cancer; Hepatocellular carcinoma; Discovery and development of mTOR inhibitors; Immunotherapy; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001973923,0.0008367125,0.002659862,0.0004609993,0.0001027513,0.00004702731,0.0002807704,0.0001353152,0.0001327142],"category_scores_gemma":[0.00003150884,0.0006259091,0.00074025,0.0002466905,0.000185765,0.0001148461,0.0002517416,0.0006422946,0.00002239237],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004770323,"about_ca_system_score_gemma":0.0007240231,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002422683,"about_ca_topic_score_gemma":0.000002368769,"domain_scores_codex":[0.9965861,0.0002420514,0.001231808,0.0009043064,0.000562777,0.0004728988],"domain_scores_gemma":[0.997143,0.0001485487,0.001364613,0.000714771,0.0003217306,0.0003073162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004803761,0.000236584,0.01223711,0.1591948,0.0003743373,0.00005059137,0.002306028,1.545863e-7,2.168979e-7,0.000117312,0.001045014,0.8243899],"study_design_scores_gemma":[0.002335088,0.0005532137,0.03086348,0.0899425,0.002381376,0.000008375012,0.001020843,0.000002195447,0.00001423773,0.00006291482,0.8722399,0.0005758615],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003595725,0.9941847,0.00007817586,0.00001247632,0.001673112,0.002716051,0.0002814489,0.00001609149,0.0006783566],"genre_scores_gemma":[0.00484346,0.9924045,0.0003184667,0.000001870146,0.0002736194,0.0002900679,0.001637054,0.00006678442,0.0001642111],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8711949,"threshold_uncertainty_score":0.9996192,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2710818547800087,"score_gpt":0.4488700099819271,"score_spread":0.1777881552019184,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}